AVROBIO is a clinical-stage gene therapy company focused on developing potentially curative ex vivo lentiviral gene therapies to treat patients with rare diseases following a single dose treatment regimen. Co.'s gene therapies employ hematopoietic stem cells (HSC) that are harvested from the patient and then modified with a lentiviral vector to insert the functional copy of the gene that is mutated in the target disease. Co. has four HSC gene therapy programs: VR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II; and AVR-RD-03 for the treatment of Pompe disease. The AVRO stock yearly return is shown above.
The yearly return on the AVRO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVRO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|